Abstract:To discover common and sub-type specific somatic alterations affecting key biological processes in pediatric cancers, we analyzed point mutations, copy number alterations, gene fusions and structural alterations detected from paired tumor-normal whole genome sequencing (n=655), whole exome sequencing (n=1,108), and RNA-seq data (n=913) of 1,705 leukemia and solid tumors. Our cohort consists of 693 B-lineage Acute Lymphoblastic Leukemia (B-ALL), 264 T-ALL, 211 Acute Myeloid Leukemia (AML), 318 Neuroblastoma (NBL), 128 Wilms Tumor (WT), and 91 Osteosarcoma (OS) with a median mutation rate of 0.28-0.58 per Mb. We identified 130 potential driver genes based on significance of variant recurrence and pathogenicity within each cancer type and across all cancer types. Seventy-two (55%) driver genes were significant in one cancer type, thirty eight were significant in > 1 leukemia subtype, thirteen (NRAS, WT1, MYCN, PTEN, TP53, KRAS, RB1, ATRX, PTPN11, MLLT1, BCOR, SETD2, NF1) were significant in both leukemia and solid tumor while the remaining seven (MGA, SF3B1, ASXL1, BCORL1, STAG2, ACTB, NIPBL) were significant only in pan-cancer analysis. The number of mutated driver genes per sample ranged from 0.8 in WT to 5.8 in T-ALL, lower when considering only point mutations (from 0.3 in NBL to 3.1 in T-ALL). The most frequently mutated biological processes affecting both leukemia and solid tumor were transcription factors (56% of samples), cell cycle (41%), epigenetic regulators (36%), Ras signaling (21%), PI-3K (11%), and the MYC complex (7%). By contrast, the JAK signaling pathway was mutated only in leukemia (16%) while mutations in the NOTCH signaling pathway were exclusive to T-ALL (77%). Aberrant transcription may also affect the normal function of a driver gene. For example, the RAS signaling pathway was mutated in B-ALL (35%), T-ALL (15%), AML (37%) and NBL (4.3%). Aside from the known KRAS 4a isoform found in all cancer types, we discovered two novel KRAS isoforms present in 71.1% of B-ALL, 67.9% of T-ALL, 71.3% of AML and 3.0% of NBL but not in WT or OS. Allele-specific expression (ASE) was detected in 205 (6.8%) of 3,016 expressed somatic mutations, and 97% (32 out of 33) of truncation mutations on autosomes exhibit reduced expression of the mutant allele likely due to nonsense mediated decay. Two ASE mutations, WT1 D447N in a cytogenetically normal AML and JAK2 D873N in a B-ALL, were selected for single-cell sequencing and successfully validated. Only 44% of our driver genes match those identified in adult cancer. This, coupled with our finding that point mutations only accounted for 48% of the driver alterations, may provide new insight into the design of precision treatment for pediatric cancer. Our presented data will be made public at NCI’s Genome Data Commons (gdc.cancer.gov) and can be explored on our ProteinPaint data portal (pecan.stjude.org). Citation Format: Xiaotu Ma, Yu Liu, Yanling Liu, Michael Edmonson, Charles Gawad, Xin Zhou, Yongjin Li, Michael Rusch, John Easton, Mark Wilkinson, Leandro C. Hermida, Sean Davis, Malcolm Smith, Jaime Guidry Auvil, Paul Meltzer, Ching C. Lau, Elizabeth Perlman, John M. Maris, Soheil Meshinchi, Stephen P. Hunger, Daniela S. Gerhard, Jinghui Zhang. Comparison of somatic alterations in the genome and transcriptome of 1,705 pediatric leukemia and solid tumors: a report from the Children’s Oncology Group (COG) - NCI TARGET Project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3004. doi:10.1158/1538-7445.AM2017-3004

The Landscape of Somatic Mutations in Epigenetic Regulators Across 1,000 Paediatric Cancer Genomes

Pan-cancer Genome and Transcriptome Analyses of 1,699 Paediatric Leukaemias and Solid Tumours.

The Landscape of Genomic Alterations Across Childhood Cancers.

Spectrum and Clinical Features of Gene Mutations in Chinese Pediatric Acute Lymphoblastic Leukemia

The Pediatric Cancer Genome Project

The genomic landscape of pediatric acute lymphoblastic leukemia

The Genomic Landscape of Childhood and Adolescent Melanoma.

Supplementary Tables from Genomes for Kids: the Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing

Abstract 3004: Comparison of Somatic Alterations in the Genome and Transcriptome of 1,705 Pediatric Leukemia and Solid Tumors: a Report from the Children’s Oncology Group (COG) - NCI TARGET Project

Supplementary Figures S1-S10 from Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations Across Tumor Spectra

The Neoepitope Landscape in Pediatric Cancers.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra

Abstract 2628: Molecular Diagnosis for Pediatric Cancer Through Integrative Analysis of Whole-Genome, Whole-Exome and Transcriptome Sequencing

Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group

Abstract 4869: Whole Genome Sequence Analysis of MLL Rearranged Infant Acute Lymphoblastic Leukemias Reveals Remarkably Few Somatic Mutations: A Report from the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project

Abstract PR01: Global Chromatin Profiling Identifies NSD2 Mutations in Pediatric Acute Lymphoblastic Leukemia

EPCO-51. FUNCTIONAL ANALYSIS OF REGULATORY MUTATIONS IN PEDIATRIC BRAIN TUMORS

Molecular Genomic Landscape of Pediatric Solid Tumors in Chinese Patients: Implications for Clinical Significance

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Key Pathways Are Frequently Mutated in High-Risk Childhood Acute Lymphoblastic Leukemia: a Report from the Children's Oncology Group.

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer